India Supreme Court Rules in Favor of Merck in Diabetes Drug Patent Suit

Source: Reuters

May 19, 2015

The Supreme Court of India has barred Mumbai-based Glenmark Pharmaceuticals from making and selling generic versions of U.S. drugmaker Merck's diabetes drugs, Januvia and Janumet.

India's Supreme Court -- widely seen as biased in favor of boosting the local generic drugs industry -- did state in court documents that Glenmark is permitted to continue to sell existing inventory of the Merck drugs.

Merck brought the lawsuit against Glenmark in 2013 for infringing a patent it has on sitagliptin, the API used in Januvia and Janumet.

Read the Reuters article



Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments